İnci Elif ERBAHÇECİ TİMUR, Nagihan UĞURLU

Prioritising of Retinal Diseases During Covid-19 Outbreak

Purpose: The aim of this study was to determine a management strategy for patients with retinal diseases to minimise the potential risk of visual impairment due to the postponement of treatments and visits during the lockdown for COVID-19. Methods: Records of all patients who had rescheduled for retina appointments from March 20, 2020, to June 1, 2020, were identified to evaluate the details regarding best-corrected visual acuity (BCVA) before the COVID-19 pandemic (V0 visit) and at the first visit after lockdown (V1 visit); primary diagnosis, duration of postponement (weeks), change in Snellen line and intravitreal injection (IVI) requirement were recorded. Patients were rescheduled according to our diagnosis-based triage practice pattern; emergency, Group 1; urgent, Group 2; routine, Group 3; and elective, Group 4. BCVA, loss of Snellen line, IVI requirement, and duration of postponement were compared between V0 and V1 visits. In addition, BCVA, change in Snellen line, and the relationship between loss in Snellen line and duration of postponement was evaluated in intravitreally injected patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Results: A total of 1,383 eyes of 763 patients were recruited in this study. The difference in BCVA at V0 visit was statistically significant among the groups and better in Group 4 (p<0.000). BCVA at V1 visit was worse in group 1 and statistically different between groups (p<0.001). BCVA was also worse at V1 visit than V0 visit in groups 1 and 2 (p<0.001 and p=0.003). Patients with nAMD had more loss in Snellen line than patients with DME in Group 1 who were injected intravitreally (p=0.004). Conclusion: These results can support retina specialists in anticipating the possible clinical consequences of outbreaks on retina patients and developing successful management strategies.

Keywords:

COVID-19, coronavirus outbreak prioritising, retinal diseases,

PDF

___

1.Guan W-J, Ni Z-Y, Hu Y. Clinical Characteristics ofCoronavirus Disease 2019 in China. N Engl J Med.2020:1–13.
2.Cucinotta D, Vanelli M. WHO Declares COVID-19 aPandemic. Acta Biomed. 2020;91(1):157–160.
3.Jee Y. WHO International Health RegulationsEmergency Committee for the COVID-19 outbreak.Epidemiol Health. 2020;42:e2020013. doi:10.4178/epih.e2020013.
4.Bakri SJ, Thorne JE, Ho AC et al. Safety and Efficacyof Anti-Vascular Endothelial Growth FactorTherapies for Neovascular Age-Related MacularDegeneration: A Report by the American Academy ofOphthalmology. Ophthalmology. 2019;126(1):55-63.doi: 10.1016/j.ophtha.2018.07.028.
5.Freund KB, Korobelnik JF, Devenyi R, et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina. 2015;35(8):1489-506.
6. Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent macular thickening following intravitreousaflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136:257–69.
7.Schmidt-Erfurth U, Lang GE, Holz FG, et al.RESTORE Extension Study Group (2014) Three yearoutcomes of individualized ranibizumab treatmentin patients with diabetic macular edema: theRESTORE extension study. Ophthalmology. 2014;121:1045–53.
8.American Academy of Ophthalmology (2020)Important coronavirus updates for ophthalmologists. March 31, 2020 https://www.aao.org/education/headline/alert-important-coronavirus-context
9.Kodjikian L. Quelleconduite à tenir adopter vis àvis des injections intravitréennes (IVT)danscettepérioded’épidémie au Covid-19 – SARS-CoV-2 ? [How to approach intravitreal injectionsduring this COVID-19 pandemic ?]. J Fr Ophtalmol.2020;43(6):539-540. doi:10.1016/j.jfo.2020.04.019.
10.Nguyen AX, Gervasio KA, Wu AY. Differences inSARS-CoV-2 recommendations from majorophthalmology societies worldwide. BMJ OpenOphthalmol. 2020;5(1):e000525.
11.Lim LW, Yip LW, Tay HW et al. Sustainablepractice of ophthalmology during COVID-19:challenges and solutions. Graefes Arch ClinExpOphthalmol. 2020;258(7):1427-36. doi: 10.1007/s00417-020-04682-z.
12.Hahn P, Blim JF, Packo K, et al. The Impact ofCOVID-19 on US and International RetinaSpecialists, Their Practices, and Their Patients. JVitreoretin Dis. 2021;6(1):40-6. doi:10.1177/24741264211034112
13.Chaudhary V, Rosenberg D, Barbosa J, et al.National survey of Canadian Retina Societymembers on guidelines for ophthalmic care duringthe COVID-19 crisis: Canadian Retina ResearchNetwork (CR2N) COVID-19 Steering Committeeanalysis. Can J Ophthalmol. 2020;55(5):452-4. doi:10.1016/j.jcjo.2020.06.001.
14.Hu V, Wolvaardt E. Ophthalmology duringCOVID-19: who to see and when. Community EyeHealth. 2020;33(109):20-3.
15.Viola F, Milella P, Giuffrida FP, Ganci S, InvernizziA.The impact of coronavirus disease (COVID-19)pandemic on intravitreal injections treatment formacular diseases: report from a referral hospital inMilan. Retina. 2021;14(4):701-5.
16.Enli TF, Koyuncu E, Özel Ş. A review of protectiveand risk factors affecting psychosocial health ofhealthcare workers in pandemics. Ankara Med J.2020; 20: 488-504.
17.Yalçın G, Sayınbatur B, Karay E, Karakaş M.Psychological Stress of Healthcare Workers Causedby the COVID-19 Pandemic. Dicle Med J.2020;47(3):525-41.